中国のTAVR（経カテーテル大動脈弁植え込み術）市場は、2026年に16億6,914万ドルに達し、2022年から2026年までに55.50％のCAGRで成長すると予想されます。一方、中国のTMVI（経カテーテル的僧帽弁植込み術/形成術）市場は、2026年に7億4,124万ドルに達し、2022年から2026年までに147.16％のCAGRが見込まれます。大動脈弁狭窄症の有病率の増加、新しいTAVR製品の承認の増加、高齢者人口の増加、急速な都市化などの要因が市場の成長を促進します。一方で、TAVRに関連するリスクとTMVIにおける患者選択という問題が市場の成長を抑制する可能性があります。いくつかの注目すべき動向としては、TAVRおよびTMVI手術の普及率の上昇、経カテーテル僧帽弁手術の価格の下落、今後の主要なTMVI製品、開心術における合併症の増加などがあります。
現在、心臓弁の介入療法は急速に進んでおり、外科的リスクが高く、健康状態が悪く、その他の合併症を伴う高齢患者に適した、安全で低侵襲の治療法と見なされています。技術開発によって、介入療法の適応が広がっています。
特に、革新的な医療機器を奨励する中国の有利な政策に後押しされて、ますます多くの医療機器メーカーが中国での経カテーテル心臓弁修復および交換製品の研究開発の競争に参加しています。国内の主要なプレーヤー間の活発な研究開発活動が新製品の発売を促進し、中国のTAVRおよびTMVI市場の成長を促すでしょう。
目次
1. Overview
1.1 Overview of Valvular Heart Diseases
1.2 Transcatheter Aortic Valve Replacement (TAVR)
1.3 Comparison Between Types of Valves in TAVR
1.4 Transcatheter Mitral Valve Replacement (TMVR)
1.5 Technical Challenges Between TAVR vs. TMVR
1.6 Manufacturing Process Of Artificial Valves
1.7 Current State and Unmet Needs of Interventional Therapy in China
2. COVID-19 Impact
2.1 Decline in Hospital Visits
2.2 Fall in Number of Merger & Acquisition (M&A) Deals
3. China Market Analysis
3.1 China Transcatheter Aortic Valve Replacement (TAVR) Market by Value
3.2 China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value
3.3 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume
3.4 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast
3.5 China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast
3.6 China Transcatheter Mitral Valve (TMV) Market Forecast by Value
3.6.1 China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value
3.6.2 China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value
3.7 China Transcatheter Mitral Valve (TMV) Treated Patient Volume Forecast
3.7.1 China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast
3.7.2 China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast
3.8 China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Prevalence of Aortic Stenosis
4.1.2 Rise in Approval of New TAVR Products
4.1.3 Rise in Geriatric Population
4.1.4 Rapid Urbanization
4.2 Key Trends
4.2.1 Rising Penetration of TAVR and TMV Procedures
4.2.2 Decline in Prices of Transcatheter Mitral Valve Procedures
4.2.3 Upcoming Major TMVI Products
4.2.4 Rise in Complications in Open-heart Surgery
4.3 Challenges
4.3.1 Risks Associated with TAVR Procedures
4.3.2 Challenge of Patient selection in TMVI
5. Competitive Landscape
5.1 China Market
5.1.1 Key Players - Revenue Comparison
5.1.2 Key Players - R&D Expenditure Comparison
5.1.3 Key Players - Market Capitalization Comparison
5.1.4 Key Players - Second-generation TAVR Product Comparison
6. Company Profiles
6.1 Medtronic PLC
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Edwards Lifesciences
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Venus MedTech HangZhou Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 MicroPort CardioFlow Medtech Corporation
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 Peijia Medical
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
List of Figures
Types of Valvular Heart Diseases
Manufacturing Process Of Artificial Valves
Number of Hospital Visits in China (2019-2020)
Number of M&A deals in the Medical Device Sector in China (2019-2020)
China Transcatheter Aortic Valve Replacement (TAVR)Market by Value (2017-2021)
China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value (2022-2026)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume (2017-2021)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast (2022-2026)
China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast (2021-2026)
China Transcatheter Mitral Valve (TMV) Market Forecast by Value (2021-2026)
China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value (2023-2026)
China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value (2023-2026)
China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast (2023-2026)
China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast (2023-2026)
China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast (2021-2026)
China Prevalence of Aortic Stenosis (2017-2021)
China Population - Aged above 65 Years (2017-2021)
China Urban Population (2017-2021)
Penetration Rate of TAVR and TMV Procedures in China (2022-2026)
Average Prices of TMVI and TMVR in China (2023-2026)
Medtronic PLC Net Sales and Net Income (2017-2021)
Medtronic PLC Net Sales by Segment (2021)
Edwards Lifesciences Net Sales and Net Income (2017-2021)
Edwards Lifesciences Net Sales by Segment (2021)
Edwards Lifesciences Net Sales by Product Area (2021)
Venus MedTech HangZhou Inc. Revenue and Loss (2017-2021)
Venus MedTech HangZhou Inc. Revenue by Region (2021)
MicroPort CardioFlow Medtech Corporation Revenue and Loss (2017-2021)
MicroPort CardioFlow Medtech Corporation Revenue by Region (2021)
Peijia Medical Revenues and Loss (2017-2021)
Peijia Medical Revenues by Segment (2021)
List of Tables
Comparison Between Types of Valves in TAVR
Technical Challenges Between TAVR vs. TMVR
Major Approved and Marketed TAVR Products in China (2017-2021)
Upcoming Major TMVI Products
Risks Associated with TAVR Procedures
Key Players - Revenue Comparison (2021)
Key Players - R&D Expenditure Comparison (2021)
Key Players - Market Capitalization Comparison (2022)
Key Players - Second-generation TAVR Product Comparison
